Biological evaluation of glucose and deoxyglucose derivatives radiolabeled with [99mTc(CO)3(H2O)3]+ core as potential melanoma imaging agents.

[1]  Marcelo Fernández,et al.  Preparation and primary bioevaluation of 99mTc-labeled-1-thio-β-D-glucose as melanoma targeting agent. , 2011, Current radiopharmaceuticals.

[2]  S. Deutscher,et al.  Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model. , 2011, Nuclear medicine and biology.

[3]  T. Quinn,et al.  Synthesis and assessment of 99mTc chelate-conjugated bevacizumab for development of specific radiopharmaceutical , 2010 .

[4]  Angélica Figueroa,et al.  Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy , 2010, International journal of endocrinology.

[5]  Junbo Zhang,et al.  Synthesis and biological evaluation of a novel 99mTc(CO)3 complex of ciprofloxacin dithiocarbamate as a potential agent to target infection. , 2010, Bioorganic & medicinal chemistry letters.

[6]  T. Storr,et al.  Cationic technetium and rhenium complexes with pendant carbohydrates. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[7]  R. J. Alves,et al.  A novel D-glucose derivative radiolabeled with technetium-99m: synthesis, biodistribution studies and scintigraphic images in an experimental model of Ehrlich tumor. , 2010, Bioorganic & medicinal chemistry letters.

[8]  P. Garg,et al.  Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors. , 2009, Bioconjugate chemistry.

[9]  M. Mihm,et al.  Current concepts of metastasis in melanoma. , 2008, Expert review of dermatology.

[10]  R. Saw,et al.  Imaging in cutaneous melanoma , 2008, Nuclear medicine communications.

[11]  R. Alberto,et al.  Technetium and rhenium: coordination chemistry and nuclear medical applications , 2006 .

[12]  C. Decristoforo,et al.  [99mTc]HYNIC-RGD for imaging integrin αvβ3 expression , 2006 .

[13]  Boli Liu,et al.  Synthesis and biological evaluation of technetium-99m-labeled deoxyglucose derivatives as imaging agents for tumor. , 2006, Bioorganic & medicinal chemistry letters.

[14]  A. Scott,et al.  Role of nuclear medicine in the management of cutaneous malignant melanoma. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  S. Oliveria,et al.  Sun exposure and risk of melanoma , 2005, Archives of Disease in Childhood.

[16]  I. Brink,et al.  Factors Influencing [F‐18] 2‐Fluoro‐2‐Deoxy‐d‐Glucose (F‐18 FDG) Uptake in Melanoma Cells: The Role of Proliferation Rate, Viability, Glucose Transporter Expression and Hexokinase Activity , 2005, The Journal of dermatology.

[17]  T. Quinn,et al.  Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. , 2003, Bioconjugate chemistry.

[18]  David J. Yang,et al.  Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. , 2003, Radiology.

[19]  R. Schibli,et al.  Current use and future potential of organometallic radiopharmaceuticals , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  C. Lindsley,et al.  A general Staudinger protocol for solution-phase parallel synthesis , 2002 .

[21]  R. Schibli,et al.  Derivatization of glucose and 2-deoxyglucose for transition metal complexation: substitution reactions with organometallic 99mTc and Re precursors and fundamental NMR investigations. , 2001, Chemistry.

[22]  R. Wahl.  Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.